

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CONNEQT HEALTH LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Craig Cooper
Date of last notice	1 September 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<u>C2 Ventures Pty Ltd</u> Craig Cooper is a controller of this entity.
Date of change	25 September 2026
No. of securities held prior to change	<u>Direct Interests</u> • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 20,058,074 FPO <u>C2 Ventures Pty Ltd</u> • 303,705,164 FPO shares • 2,000,000 Convertible Notes as approved by Shareholders at the 14 April 2026 EGM

Appendix 3Y
Change of Director's Interest Notice

Class	As above
Number acquired	<u>C2 Ventures Pty Ltd</u> 68,181,818 FPO shares via Tranche 2 Placement and Shareholder approval received 15 September 2026
Number disposed	<u>C2 Ventures Pty Ltd</u> 27,272,727 FPO via Off Market Transfer 2,000,000 Convertible Notes converted
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquired <u>C2 Ventures Pty Ltd</u> - A\$1,500,000 - 68,181,818 FPO Disposal <u>C2 Ventures Pty Ltd</u> \$NIL - 27,272,727 FPO \$NIL - 2,000,000 Convertible Notes converted
No. of securities held after change	<u>Direct Interests</u> 2,000,000 Performance Rights expiring 30 November 2027 7,500,000 Performance Rights expiring 9 May 2030 10,000,000 Performance Rights expiring 31 August 2030 20,058,074 FPO <u>C2 Ventures Pty Ltd</u> 344,614,255 FPO shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquired <u>C2 Ventures Pty Ltd</u> 68,181,818 FPO via Tranche 2 Placement and Shareholder approval obtained on 15 September 2026 Disposal <u>C2 Ventures Pty Ltd</u> 27,272,727 FPO via Off Market Transfer 2,000,000 Convertible Notes converted

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A as no interest in contracts.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No, as no securities traded.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	CONNEQT HEALTH LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Niall Cairns
Date of last notice	1 September 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<u>C2 Ventures Pty Ltd</u> Niall Cairns is a controller of this entity. <u>Carnethy Evergreen Pty Ltd</u> Niall Cairns is the controller of this entity. <u>Carnethy Investments Pty Ltd</u> Niall Cairns is the controller of this entity.
Date of change	25 September 2026

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<u>Direct Interests</u> • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 1,250,000 FPO shares <u>C2 Ventures Pty Ltd</u> • 303,705,164 FPO shares • 2,000,000 Convertible Notes as approved by Shareholders at the 14 April 2026 EGM <u>Carnethy Evergreen Pty Ltd</u> • 14,084,204 FPO shares <u>Carnethy Investments Pty Ltd</u> • 14,581,638 FPO shares
Class	As above
Number acquired	<u>C2 Ventures Pty Ltd</u> • 68,181,818 FPO shares via Tranche 2 Placement and Shareholder approval received 15 September 2026 <u>Carnethy Evergreen Pty Ltd</u> • 27,272,727 FPO shares via Off Market Transfer • <u>Carnethy Investments Pty Ltd</u> • 1,022,728 FPO shares via Off Market Transfer
Number disposed	<u>C2 Ventures Pty Ltd</u> • 27,272,727 FPO via Off Market Transfer • 2,000,000 Convertible Notes converted <u>Carnethy Evergreen Pty Ltd</u> • 1,022,728 FPO shares via Off Market Transfer

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquired <u>C2 Ventures Pty Ltd</u> • A\$1,500,000 - 68,181,818 FPO <u>Carnethy Evergreen Pty Ltd</u> • \$NIL - 27,272,727 FPO <u>Carnethy Investments Pty Ltd</u> • \$NIL - 1,022,728 FPO Disposal <u>C2 Ventures Pty Ltd</u> • \$NIL - 27,272,727 FPO • \$NIL - 2,000,000 Convertible Notes converted <u>Carnethy Evergreen Pty Ltd</u> • \$NIL - 1,022,728 FPO
No. of securities held after change	<u>Direct Interests</u> • 2,000,000 Performance Rights expiring 30 November 2027 • 7,500,000 Performance Rights expiring 9 May 2030 • 10,000,000 Performance Rights expiring 31 August 2030 • 1,250,000 FPO shares <u>C2 Ventures Pty Ltd</u> • 344,614,255 FPO shares <u>Carnethy Evergreen Pty Ltd</u> • 40,334,203 FPO shares <u>Carnethy Investments Pty Ltd</u> • 15,604,366 FPO shares

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquired <u>C2 Ventures Pty Ltd</u> 68,181,818 FPO via Tranche 2 Placement and Shareholder approval obtained on 15 September 2026 <u>Carnethy Evergreen Pty Ltd</u> 27,272,727 FPO via Off Market Transfer <u>Carnethy Investments Pty Ltd</u> 1,022,728 FPO via Off Market Transfer Disposal <u>C2 Ventures Pty Ltd</u> 27,272,727 FPO via Off Market Transfer 2,000,000 Convertible Notes converted <u>Carnethy Evergreen Pty Ltd</u> 1,022,728 FPO shares via Off Market Transfer
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A as no interest in contracts.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No, as no securities traded.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CARDIEX LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Randall King Nelson
Date of last notice	31 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	2 October 2026
No. of securities held prior to change	<u>Direct Interests</u> • 15,385 FPO • 500,000 Options at \$0.50 expiring 16 December 2027 • 1,000,000 Quoted Options at \$0.20 expiring 30 November 2025
Class	As above
Number acquired	NIL
Number disposed	• 15,385 FPO • 1,000,000 Quoted Options at \$0.20 expiring 30 November 2025

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	• \$0.03 per share • NIL – expired Options
No. of securities held after change	<u>Direct Interests</u> • 500,000 Options at \$0.50 expiring 16 December 2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	• Share Buy Back • Quoted Options expired

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A as no interest in contracts.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A as no securities traded.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	CONNEQT HEALTH LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Charlie Taylor
Date of last notice	29 April 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<u>CW Taylor Family Trust</u> Charlie Taylor is a controller and beneficiary of this entity.
Date of change	25 September 2026
No. of securities held prior to change	<u>Indirect</u> CW Taylor Family Trust • 1,975,002 FPO
Class	As above
Number acquired	<u>Indirect</u> CW Taylor Family Trust • 1,636,364 FPO shares in lieu of director fees as approved by Shareholders at the 15 September 2026 EGM
Number disposed	NIL

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquired <u>Indirect</u> CW Taylor Family Trust 1,636,364 FPO shares in lieu of director fees equivalent to \$36,000 as approved by Shareholders at the 15 September 2026 EGM
No. of securities held after change	<u>Indirect</u> CW Taylor Family Trust 3,611,366 FPO
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquired <u>Indirect</u> CW Taylor Family Trust 1,636,364 FPO FPO shares in lieu of director fees as approved by Shareholders at the 15 September 2026 EGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A as no interest in contracts.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No, as no securities traded.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.